

Supplementary Table 20: Number and proportion of patients receiving concomitant treatment with immunomodulators in 1L

Indication	Advanced therapy	Total number of patients	AZA / 6-MP (n, %)	MTX (n, %)
CD	Adalimumab	923	142 (15.4%)	28 (3.0%)
CD	Infliximab	616	140 (22.7%)	15 (2.4%)
CD	Ustekinumab	113	9 (8.0%)	n < 5
CD	Vedolizumab	139	8 (5.8%)	n < 5
UC	Adalimumab	337	55 (16.3%)	11 (3.3%)
UC	Golimumab	111	16 (14.4%)	n < 5
UC	Infliximab	419	105 (25.1%)	5 (1.2%)
UC	Tofacitinib	17	0 (0.0%)	0 (0.0%)
UC	Ustekinumab	25	0 (0.0%)	n < 5
UC	Vedolizumab	248	28 (11.3%)	n < 5

AZA = azathioprine, 6-MP = 6-mercaptopurine, MTX = methotrexate, CD = Crohn's disease, UC = ulcerative colitis

Some groups could not be reported due to data protection reasons (n < 5).